news
Tool to track SARS-CoV-2 mutations could inform drug development
A new tool called COVID-3D that monitors SARS-CoV-2 genome mutations could aid drug and vaccine development, its creators say.
List view / Grid view
Research & Development
news
Concanamycin A antibiotic that targets Nef protein could cure HIV
Researchers have revealed that the antibiotic concanamycin A targets a protein called Nef, allowing the immune system to destroy HIV in cells.
news
Researchers capture images of cells infected with SARS-CoV-2
Using scanning electron microscopy, researchers have captured images of epithelial cell cultures infected by SARS-CoV-2.
article
Advancing cell therapies with engineered Tregs
Regulatory T cells (Tregs) play a key role in regulating our immune system and inflammatory processes. Sangamo Therapeutics is evaluating the potential of CAR-Tregs (Tregs genetically modified with a chimeric antigen receptor, or CAR) for the development of therapies for immunological diseases, such as Crohn’s disease and multiple sclerosis, as…
article
Flow cytometry in neglected tropical diseases – a focus on leishmaniasis
The World Health Organization (WHO) identifies leishmaniasis as a neglected tropical disease for which new treatments are vitally needed. Leishmaniasis primarily affects people in South America, East Africa and Asia, especially those weakened by malnutrition and poverty. To help those with this disfiguring and potentially life-threatening parasitic disease, the European…
news
Two drug candidates show promise against COVID-19 in organoid system
Following their success in organoid systems, two drug candidates are now to be administered to ferrets and tested against COVID-19.
news
Researchers visualise how orthoreovirus assembles inside infected cells
Researchers have captured the assembly of orthoreovirus, part of the Reoviridae family, inside infected cells using cryo-electron tomography.
news
Human genome-produced RNA discovered on surface of cells
Human genome-produced RNA has been found on the surface of human cells, which researchers say could be easier for therapeutics to reach.
article
Antibody therapeutics for COVID-19
In 2019, the SARS-CoV-2 coronavirus sparked a global pandemic that is likely to continue into 2021. Effective therapeutics that treat the symptoms of the disease and prevent or treat the underlying viral infection are critically required. To meet this need, the global biopharmaceutical industry is evaluating over 50 monoclonal antibody…
article
Defusing antibody neutralisers in AAV gene therapy
Adeno-associated virus (AAV)-mediated gene therapies allow for the treatment of a growing number of diseases; however, the presence of neutralising antibodies can lead to limitations of this technology, particularly for patients who may be excluded due to these pre-existing or developing neutralising antibodies. Recently, a study was published in Nature…
article
SARS-CoV-2, a spillover from animals to man, a spillback from man to animals and… what next?
Professor Giovanni Di Guardo discusses the relationship between animals and humans in regards to the transmission of SARS-CoV-2.
article
Targets In-Depth Focus 2020
This in-depth focus includes articles on the importance of a novel target to treat M. tuberculosis infections and how recently identified interactions between the SARS-CoV-2 Spike protein and host epithelial cells could be used in the development of COVID-19 therapeutics.
news
Study shows how cone cells in the retina form connections with brain
Researchers have discovered how cone cells in the retina send information to the brain, which could be used in the development of treatments for blindness.
news
Genetic analysis reveals disease-causing protein drug targets
An analysis of blood protein levels has supported drug target prioritisation by identifying the causal effects of proteins on diseases, a team has shown.
article
Drug Target Review – Issue 3 2020
This issue includes articles that explore how a next-generation genomics platform can be used for COVID-19 research, the elimination of neutralising AAV antibodies for gene therapies and a new quick and cost-effective biomarker technology for cancer diagnostics. Also in this issue are features on antibody therapeutics for COVID-19 and targets…